Serum Institute of India plans to manufacture Ebola vaccine for use in Uganda outbreak

The source said the Ebola vaccine doses would be supplied free of cost.;

Published On 2022-10-19 09:00 GMT | Update On 2024-02-15 02:56 GMT

New Delhi: The Serum Institute of India plans to manufacture 20,000 to 30,000 doses of an experimental Ebola vaccine by the end of November for use in trials against an outbreak in Uganda, its developers and a company source said.

The response to Uganda's outbreak has been blunted by the absence of a proven vaccine against the Sudan strain of the virus.

There have been 54 confirmed cases and 19 deaths since last month, and the first case in the capital, Kampala, was recorded last week. But health authorities believe the actual numbers could be higher.

Vaccines against the more common Zaire strain of Ebola have proven highly effective during recent outbreaks in neighbouring Democratic Republic of Congo.

Oxford University's Jenner Institute, which developed a COVID-19 vaccine with AstraZeneca, has an Ebola vaccine that has been shown to induce an immune response to both the Sudan and Zaire strains in Phase 1 trials.

Its developers said it could be deployed in Uganda as part of a clinical trial once the authorities there gave regulatory approval.

"We are working very closely with Serum Institute to rapidly scale up the manufacture of this vaccine," said Teresa Lambe, the chief scientific adviser on Ebola at the Jenner Institute.

"We are hoping to have a large number of doses, approximately 20,000 to 30,000 or more by mid-to-end of November," she told Reuters.

A source at the Serum Institute, the world's biggest vaccine maker and part of a conglomerate run by Indian billionaire Cyrus Poonawalla, confirmed this information. The source said the Ebola vaccine doses would be supplied free of cost.

'PLAYING CATCH UP'

Uganda's Information Minister Chris Baryomunsi said in an interview on Saturday that he did not have any information on a vaccine rollout but that the outbreak was under control.

President Yoweri Museveni said the same day that the government would implement an overnight curfew and restrict movement into and out of two districts in central Uganda affected by Ebola for 21 days.

World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus said last week that clinical trials of two vaccines could begin in the coming weeks pending Ugandan government approvals, without naming the vaccines.

There are at least six vaccines in development for the Sudan strain, including three with Phase 1 data, according to WHO.

The Oxford researchers voiced frustration that their vaccine was not ready to be rolled out when the outbreak hit, saying governments around the world had not made investing in vaccines enough of a priority in the wake of the COVID-19 pandemic.

The vaccine has been in development for several years, but its progress through clinical trials has been slowed by funding shortfalls, they said.

"With the better investment, the world could easily have ready-made vaccines sitting in vials for this and a number of other diseases," said Sandy Douglas, an investigator at the Jenner Institute.

"We're spending a couple of months now playing catch up on work that could have been done ahead of time."

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Serum Institute of India plans to manufacture Ebola vaccine for use in Uganda outbreak

The source said the Ebola vaccine doses would be supplied free of cost.;

Similar News

Granules India arm gets 1 USFDA observation for Hyderabad facility

CDSCO Panel Clears PURE & CURE's Sickle Cell Trial With Conditions On Sample Size, Sites

Sun Pharma net profit drops 20% to Rs 2,279 crore in Q1

Sandoz to acquire Just-Evotec Biologics EU SAS in-house development, manufacturing capabilities in France

Zydus Wellness sees exit of Head-R&D, Head-GDSO

Natco Pharma appoints TC Mallikarjun as Vice President - QC at Kothur Pharma Division

Veeda Clinical Research Gets Expert Committee Nod To Conduct BA/BE Study Of Ibrutinib For Export

Ajanta Pharma Gets Relief in Erectile Dysfunction Drug Export Case, Penalty Set Aside